Celldex Presents Results from Barzolvolimab Phase 2 Study in Cold Urticaria (ColdU) and Symptomatic Dermographism (SD) Demonstrating Sustained Efficacy and Favorable Safety Profile over 20 Week Placebo Controlled Treatment Period; Up to 66% of Patients with ColdU and 49% with SD Obtain Complete Response at Week 20 GlobeNewswire November 06, 2025 First large, randomized, placebo-controlled […]

Celldex Presents Additional Positive Data Demonstrating Barzolvolimab's Ability to Drive Rapid, Profound and Durable Complete Urticaria Control in Phase 2 Chronic Spontaneous Urticaria (CSU) Study GlobeNewswire November 06, 2025 HAMPTON, N.J., Nov. 06, 2025 (GLOBE NEWSWIRE) — Celldex (NASDAQ:CLDX) announced today new data on exploratory endpoints (UCT7) further demonstrating barzolvolimab's ability to improve urticaria control

Terra Innovatum Global to Report Third Quarter 2025 Financial Results and Provide Business Update on November 17, 2025 GlobeNewswire November 06, 2025 NEW YORK, Nov. 06, 2025 (GLOBE NEWSWIRE) — Terra Innovatum Global N.V. (“Terra Innovatum” or the “Company“) (NASDAQ: NKLR), a developer of micro-modular nuclear reactors, announced it will release its third quarter fiscal

Darktrace Recognized as the Only Customer's Choice Vendor in the 2025 Gartner(R) Peer Insights(TM) for Network Detection and Response Darktrace is the only vendor to be recognized as both a Leader in the 2025 Gartner(R) Magic Quadrant(TM) and a Customers' Choice for Network Detection and Response (NDR). Darktrace / NETWORK(TM) holds a 95% Willingness to

UroGen Reports Third Quarter 2025 Financial Results as ZUSDURI(TM) Launch Gains Momentum GlobeNewswire November 06, 2025 Reported three-month complete response rate of 77.8% from the Phase 3 UTOPIA trial of UGN-103, consistent with ENVISION results; FDA agreed to regulatory plan to submit an NDA based on data from the UTOPIA trial ZUSDURI received unique J-Code

Evotrex Exits Stealth with $16 Million Pre-A to Debut the World's First Power-Generating RV Trailer at CES 2026 Capital accelerates commercialization of innovative RV trailer to make outdoor adventure enjoyable and limitless GlobeNewswire November 06, 2025 LOS ANGELES, Nov. 06, 2025 (GLOBE NEWSWIRE) — Evotrex, a California-based company transforming the future of outdoor adventure through

Asure Software Sets November and December 2025 Investor Conference Schedule GlobeNewswire November 06, 2025 AUSTIN, Texas, Nov. 06, 2025 (GLOBE NEWSWIRE) — Asure Software, Inc. (Nasdaq: ASUR), a leading provider of cloud-based Human Capital Management software solutions, is scheduled to participate at the following financial conferences during November and December 2025: 16th Annual Craig-Hallum Alpha

Sironax Announces Three Abstracts Selected for Presentation at Neuroscience 2025 Society for Neuroscience Annual Meeting, November 15-19, San Diego, CA GlobeNewswire November 06, 2025 WALTHAM, Mass., Nov. 06, 2025 (GLOBE NEWSWIRE) — Sironax, a global clinical-stage biotechnology company dedicated to discovering and developing transformative therapies for age-related degenerative diseases, today announced the selection of three

Route 92 Medical Appoints Medtech Industry Leader Pat Mackin to its Board of Directors GlobeNewswire November 06, 2025 SAN MATEO, Calif. and WEST JORDAN, Utah, Nov. 06, 2025 (GLOBE NEWSWIRE) — Route 92 Medical, Inc., a privately held medical technology company dedicated to improving outcomes for patients undergoing neurovascular intervention, today announced the election of

Solmate Infrastructure (SLMT) Launches the UAE's First Performant Solana Validator, Announces Infrastructure Flywheel(TM) Including Planned RPC and Colocation Services GlobeNewswire November 06, 2025 Validator boasts first-ever Solana block minted in the UAE and is now open to the public at 0% commission Solmate validator to serve as foundation for new RPC and colocation infrastructure services